SCIREX Research Center
Austin, Texas, 78705, United States
NCT Number: NCT00993863
The objective of this study is to evaluate the analgesic efficacy and safety of ADL5859 compared with placebo and an active control (ibuprofen) in subjects with acute dental pain after third molar extraction.
Looking for future studies?
Notify Me18 year–50 year
All sexes
Interventional
Phase 2
Austin, Texas, 78705, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
single dose
single dose
single dose
single dose
single dose
Other names: Advil
Time frame: 4 hours after study medication
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
A Randomized, Single-Dose, Double-Blind, Active- and Placebo-Controlled Study of ADL5859 for the Treatment of Pain After Surgical Removal of Impacted Third Molars
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03836807
Acute Pain, Facial Pain
Moscow, Russia
View Trial DetailsNCT03714672
Acute Pain, Facial Pain
Zapopan, Jalisco, Mexico
View Trial DetailsNCT01490931
Acute Pain, Facial Pain
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT07735884
Acute Pain, Femoral Fractures
Lahore, Punjab Province, Pakistan
View Trial Details